FGFR2 and intrahepatic cholangiocarcinoma: In a patient with Stage IVB intrahepatic cholangiocarcinoma with FGFR2 fusion, typical pemigatinib side effects required treatment, but long‐term survival could be achieved by multidisciplinary management of side effects.